Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib

BACKGROUND: Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and resistance associated with BTK inhibition have not been characterized. Although only a small proportion of pat...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Woyach, Jennifer A., Furman, Richard R., Liu, Ta-Ming, Ozer, Hatice Gulcin, Zapatka, Marc, Ruppert, Amy S., Xue, Ling, Li, Daniel Hsieh-Hsin, Steggerda, Susanne M., Versele, Matthias, Dave, Sandeep S., Zhang, Jenny, Yilmaz, Ayse Selen, Jaglowski, Samantha M., Blum, Kristie A., Lozanski, Arletta, Lozanski, Gerard, James, Danelle F., Barrientos, Jacqueline C., Lichter, Peter, Stilgenbauer, Stephan, Buggy, Joseph J., Chang, Betty Y., Johnson, Amy J., Byrd, John C.
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4144824/
https://ncbi.nlm.nih.gov/pubmed/24869598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1400029
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki